Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and another hormone, could offer a notable development for obesity treatment. Initial human trials have demonstrated https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide